Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy
The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Primary Sponsor
The University of Sydney
Collaborating Groups
Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
Closing Date of Accrual
30 June 2019
Trial Chairperson
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
Trial Contact
nivorad@ctc.usyd.edu.au
Related Post
14 October, 2026
New FET-PET imaging approach helps target radiotherapy for glioblastoma, FIG trial – TROG 18.06 finds
LATEST NEWS: 14 October 2026 Adding a FET-PET brain
26 September, 2026
Trial finds radiation therapy halves risk of brain tumour recurrence after surgery
LATEST NEWS: 26 September 2026 Giving radiotherapy after surgery